Stimulant Medication for ADHD: How It Works and What to Expect

Stimulant medication is the first-line pharmacological treatment for ADHD in the UK ^[1]. This article covers what stimulants are, how they act on the brain, the UK licensed options, what titration usually involves, the common side effects, the safety monitoring that comes with prescribing, and how shared care between a private clinician and an NHS GP can work. It is written for adults considering or starting medication, and for parents weighing it up for a child aged 6 or over.

What stimulants are and what they do

ADHD stimulants are medications that increase the availability of two neurotransmitters in the brain: dopamine and noradrenaline. Both are involved in attention, working memory, motivation and the regulation of behaviour. The ADHD brain shows differences in dopamine and noradrenaline signalling that are well documented at the level of receptor function, transporter density and prefrontal-striatal circuit activity ^[6]. Stimulants do not add anything the brain does not already have; they slow the clearance of these neurotransmitters from the synapse so more of them are available at the right time.

Two pharmacological families are licensed in the UK for ADHD. The methylphenidate family works mainly by blocking the dopamine and noradrenaline transporters that pull these neurotransmitters back out of the synapse ^[2]. The amphetamine family, represented in the UK by lisdexamfetamine and dexamfetamine, also blocks reuptake and additionally causes increased release of dopamine and noradrenaline from the presynaptic neuron ^{[3, 4]}. The end clinical effect is broadly similar; the mechanisms are not identical, which is why one family can work where the other has not.

Stimulants are licensed under NICE NG87 as a first-line option for ADHD across all ages from age 5 upwards where pharmacological treatment is indicated ^[1]. The evidence base for short-term efficacy is among the strongest in psychiatry: a 2018 network meta-analysis published in the Lancet Psychiatry, covering 133 trials and over 14,000 participants, found stimulants outperformed placebo and non-stimulants on the primary symptom measures, with methylphenidate the best-tolerated first-line option in children and amphetamines the most efficacious option in adults ^[5].

UK licensed stimulants

There are three licensed stimulant molecules in the UK and several brands within each.

Methylphenidate

Available as both immediate-release and modified-release preparations. Immediate-release methylphenidate (often referred to generically, with Ritalin as the historical brand) acts for a few hours and is taken two or three times across the day. The modified-release brands deliver methylphenidate over a longer period from a single morning dose. UK brands include Concerta XL, Equasym XL, Medikinet XL, Xaggitin XL and Delmosart ^[2]. Each modified-release brand has a slightly different release profile; clinicians choose between them on the basis of how the school or working day is shaped and how the patient responds. Methylphenidate is licensed in the UK from age 6 ^[2].

Lisdexamfetamine (Elvanse)

A prodrug, meaning it is inactive until the body metabolises it. After oral dosing, lisdexamfetamine is gradually converted into dexamfetamine in the bloodstream, which produces a smoother and longer-acting effect than immediate-release dexamfetamine itself ^[3]. The UK brand is Elvanse, licensed from age 6 in the UK ^[3]; the separate adult presentation, Elvanse Adult, was consolidated into the single Elvanse brand in late 2025.

Dexamfetamine

Available as an immediate-release tablet or an oral solution. Shorter-acting than lisdexamfetamine; sometimes used as a top-up alongside a modified-release stimulant, or where lisdexamfetamine is not tolerated ^[4]. Licensed from age 6 ^[4].

All three are Schedule 2 controlled drugs in the UK under the Misuse of Drugs Regulations 2001, which affects how they are prescribed, dispensed and travelled with ^[8]. The clinical implications are covered in more detail in the controlled drugs article in this library.

How titration usually works

Titration is the process of starting at a low dose and gradually increasing until the right balance of benefit and side effects is found. NICE NG87 sets out the broad shape: review at least every week or two during the active titration period, and a structured review at around six weeks once a steady dose is reached ^[1]. In practice ADHD medication and titration with NeuroFX usually takes three months from first dose to a stable working regime, although some people get there sooner and some take longer.

Specific doses are not discussed in patient-facing material because they are a prescribing decision and depend on age, weight, the formulation chosen and the clinical picture. What is useful to know is the shape of titration rather than the numbers.

A typical pattern looks like:

• A low starting dose, taken at the same time each day, with food where the formulation recommends it
• A short period (often a week or two) to let any initial side effects settle
• A planned dose increase if benefit is incomplete and tolerability is good
• A second, sometimes third, increase across the following weeks
• A formal review at around six weeks once a working dose is reached, with discussion of any residual issues
• Continuing review at three months and then at intervals agreed with the prescriber

Many patients describe a "first week wobble" of headache, mild nausea or a flat mood, which usually settles within ten to fourteen days. If it does not, that is worth raising with the prescriber rather than waiting for the next planned review.

Common side effects and what tends to happen with them

The common side effects of stimulants are well characterised in the BNF and BNFc ^{[2, 3, 4]}. They include:

• Reduced appetite, particularly at lunchtime
• Difficulty getting to sleep, especially in the early weeks
• Headache, usually transient
• Dry mouth
• Mild rise in heart rate and blood pressure
• Irritability or mood flattening, particularly as the dose wears off ("rebound")
• In children, slowed growth in weight and sometimes height, which usually returns to expected trajectory after medication is stopped

Most of these settle within the first month or are manageable with practical changes (eating earlier in the day, taking the dose earlier in the morning, switching to a different release profile, hydration). A small proportion of side effects do not settle, and a switch within the methylphenidate family, between methylphenidate and amphetamine class, or to a non-stimulant becomes the right move. Around a third of patients find the first stimulant they try does not work for them; switching produces a working option for most of those ^[5]. The detail of what to expect across the first months sits in a calm guide to your first six months of titration.

Monitoring and safety

Before starting a stimulant, NICE NG87 recommends a full medical and family history, blood pressure and heart rate measurement, a check of weight (and height in children) and consideration of cardiac history ^[1]. Most clinicians take baseline measurements at the assessment and repeat them through titration and at each review.

The cardiovascular question is the one most often asked. A 2022 systematic review and meta-analysis in JAMA Network Open found that ADHD medications were associated with small increases in heart rate and blood pressure but no significant increase in serious cardiovascular events such as stroke, myocardial infarction or sudden death across the populations studied ^[7]. The clinical implication is that healthy patients with normal baseline cardiovascular measurements can usually be prescribed stimulants safely, while patients with existing cardiovascular disease, an abnormal cardiac history, or a strong family history of early sudden cardiac death warrant cardiology input before starting.

Other planned monitoring includes appetite and weight (especially in children), sleep, mood, and any unexpected behavioural change. Children also have a growth check at each review. Annual review is the long-term minimum.

Stimulants are not the whole picture

Stimulants are one part of the treatment plan, not the whole of it. NICE NG87 frames medication as part of a broader package that also includes psychoeducation, environmental adjustments and, where relevant, structured non-pharmacological support ^[1]. ADHD diagnosis is more than medication makes that case in more detail. Most adults with ADHD find the medication does the lifting on attention and emotional regulation, while the lasting change comes from what they then put in place around it.

Some people choose not to take medication, and that is a legitimate choice. Some try and stop because the side effects outweigh the benefit, or because their life circumstances have shifted. Some take a stimulant only on workdays. These are conversations to have with the prescriber rather than decisions to fear.

How NHS, Right to Choose and private prescribing fit together

Under NICE NG87, stimulants must be initiated by a healthcare professional with training and experience in diagnosing and managing ADHD ^[1]. In the UK, this means a specialist NHS service, a Right to Choose provider, or a CQC-registered private clinic. Routine prescribing can subsequently be transferred to a GP under shared care, but the initiation and titration are specialist tasks.

NHS waiting times for adult ADHD assessment have been long across most of the UK for several years. Right to Choose in England is a legal entitlement that lets a patient ask their GP to refer them to any NHS-contracted provider, often shortening the wait. Private assessment via a CQC-registered provider such as NeuroFX is faster and self-funded. Where a patient is stable on a specific medication and dose, NeuroFX will support a shared care request with the NHS GP; where the local Integrated Care Board declines shared care, NeuroFX offers continued private prescribing. The shape of this varies by area and is not a fault of any one prescriber or GP.

What this means in practice

• Stimulants are evidence-based and well tolerated for most people who take them, but they are not the whole treatment plan.
• The starting dose is almost never the right dose; expect three months of structured adjustment.
• The first week or two is often the hardest. Most early side effects settle within a fortnight.
• If the first stimulant tried does not suit, the chance of a different stimulant suiting is high. One trial does not settle the question.
• Baseline blood pressure and heart rate should be taken before starting and again across titration. If they have not been, raise it.
• Long-term review at least annually is the minimum standard, not the ceiling.

When to speak to a professional

Speak to your GP, your private prescriber or NHS 111 if a new symptom appears that worries you, if your blood pressure or heart rate feels noticeably different, or if mood, sleep or appetite changes are not settling. Seek urgent help via 999 or A&E for chest pain, shortness of breath, fainting or any acute mental health crisis. For an private ADHD assessment for adults and children aged 6 and upwards NeuroFX offers private adult ADHD assessment and paediatric ADHD assessment where the NHS wait is not workable.

Sources

1. NICE. Attention deficit hyperactivity disorder: diagnosis and management. NG87. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng87
2. British National Formulary. Methylphenidate hydrochloride. https://bnf.nice.org.uk/drugs/methylphenidate-hydrochloride/
3. British National Formulary. Lisdexamfetamine mesilate. https://bnf.nice.org.uk/drugs/lisdexamfetamine-mesilate/
4. British National Formulary. Dexamfetamine sulfate. https://bnf.nice.org.uk/drugs/dexamfetamine-sulfate/
5. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit/hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738.
6. Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews. 2021;128:789-818.
7. Zhang L, Yao H, Li L, et al. Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. JAMA Network Open. 2022;5(11):e2243597.
8. Misuse of Drugs Regulations 2001. Schedule 2. UK Statutory Instruments. https://www.legislation.gov.uk/uksi/2001/3998/contents